[Transfer of cefminox to tissues in the field of obstetrics and gynecology].
Cefminox (CMNX, MT-141), a new cephamycin, was studied of its transfer into the serum and tissues with following results: After an intravenous injection of 1 g of CMNX, the serum concentration of the drug achieved in the uterine artery was almost equal to that in the elbow vein, showing good transfer of the drug. After an intravenous injection of 1 g of CMNX, favorable results were also obtained for concentrations achieved in all of the adnexal and uterine tissues studied. From the results obtained, it is expected that CMNX is highly effective in particular for infections caused by E. coli, Klebsiella sp. and B. fragilis.
D000328:Adult; D000368:Aged; D000818:Animals; D002513:Cephamycins / Q000097:blood / Q000378:metabolism* / Q000627:therapeutic use; D004716:Endometritis / Q000188:drug therapy / Q000378:metabolism / Q000382:microbiology; D005260:Female; D005836:Genitalia, Female / Q000378:metabolism*; D006801:Humans; D007700:Kinetics; D007889:Leiomyoma / Q000378:metabolism; D008875:Middle Aged; D010053:Ovary / Q000378:metabolism; D010057:Oviducts / Q000378:metabolism; D010538:Peritonitis / Q000188:drug therapy / Q000378:metabolism / Q000382:microbiology; D014594:Uterine Neoplasms / Q000378:metabolism; D014599:Uterus / Q000378:metabolism
D002513:Cephamycins; C046079:cefminox